These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31402445)

  • 1. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
    Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
    Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Acta Obstet Gynecol Scand; 2019 Feb; 98(2):139-153. PubMed ID: 30339274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
    Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
    Lichter KE; Sheffield J; Graham EM; Eke AC
    J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.
    EPPPIC Group
    Lancet; 2021 Mar; 397(10280):1183-1194. PubMed ID: 33773630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
    Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
    Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data.
    Romero R; Conde-Agudelo A; El-Refaie W; Rode L; Brizot ML; Cetingoz E; Serra V; Da Fonseca E; Abdelhafez MS; Tabor A; Perales A; Hassan SS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Mar; 49(3):303-314. PubMed ID: 28067007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis.
    Jarde A; Lutsiv O; Beyene J; McDonald SD
    BJOG; 2019 Apr; 126(5):556-567. PubMed ID: 30480871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB; McIntire DD; Leveno KJ
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
    Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
    J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth - A Systematic Review and Meta-analysis Taking into Account the PROLONG Trial.
    Kuon RJ; Berger R; Rath W
    Geburtshilfe Frauenheilkd; 2021 Jan; 81(1):61-69. PubMed ID: 33487666
    [No Abstract]   [Full Text] [Related]  

  • 19. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis.
    Schuit E; Stock S; Rode L; Rouse DJ; Lim AC; Norman JE; Nassar AH; Serra V; Combs CA; Vayssiere C; Aboulghar MM; Wood S; Çetingöz E; Briery CM; Fonseca EB; Worda K; Tabor A; Thom EA; Caritis SN; Awwad J; Usta IM; Perales A; Meseguer J; Maurel K; Garite T; Aboulghar MA; Amin YM; Ross S; Cam C; Karateke A; Morrison JC; Magann EF; Nicolaides KH; Zuithoff NP; Groenwold RH; Moons KG; Kwee A; Mol BW;
    BJOG; 2015 Jan; 122(1):27-37. PubMed ID: 25145491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.